← Back to articles
Noetik uses transformer AI models like TARIO-2 to address the 95% failure rate in cancer drug trials by reframing the problem as one of patient-treatment matching.
Latent Space · April 20, 2026
AI Summary
- •95% of cancer treatments fail during clinical trials, representing a massive inefficiency in drug development
- •Noetik founders Ron Alfa and Daniel Bear argue the high failure rate stems from a matching problem rather than drug efficacy issues
- •The company is deploying autoregressive transformers, specifically TARIO-2, to better match patients with appropriate cancer treatments
- •This AI approach could potentially improve trial success rates by optimizing patient selection and treatment pairing
Related Articles
Large Language Models
Moonshot AI launches open-weight Kimi K2.6 model to rival closed proprietary AI systems while supporting massive agent swarms
THE DECODER·Apr 20, 2026
Large Language Models
Connie Ballmer's $80 million donation bolsters NPR as federal public broadcasting funding faces $1.1 billion cuts under Trump administration.
Fortune AI·Apr 20, 2026
Large Language Models
Researchers investigate whether models trained to avoid deceptive behavior can maintain alignment when deployed in different environments.
LessWrong AI·Apr 20, 2026
Large Language Models
AWS introduces ToolSimulator, an LLM-powered framework within Strands Evals that enables safe, scalable testing of AI agents without risking live API calls or data exposure.
Amazon AI Blog·Apr 20, 2026
Large Language Models
Custom LLM training platforms from AWS, NVIDIA, Microsoft, and OpenAI are positioned for significant growth through 2035, with major opportunities in domain-specific model training and secure cloud deployments.
Yahoo Finance AI·Apr 20, 2026
Stay ahead with AI news
Get curated AI news from 200+ sources delivered daily to your inbox. Free to use.
Get Started Free